Moderate dose capecitabine in older patients with metastatic breast cancer: A standard option for first line treatment?

Breast

Volumn 19, Issue 5, 2010, Pages 377-381

  Kotsori, A A ^a   Noble, J L ^a   Ashley, S ^a   Johnston, S ^a   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Capecitabine chemotherapy; Elderly; Metastatic

Indexed keywords

CAPECITABINE; TRASTUZUMAB;

AGED; ALOPECIA; ANEMIA; ANGINA PECTORIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRAIL ELDERLY; HAND FOOT SYNDROME; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SOFT TISSUE METASTASIS; STOMATITIS; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VISCERAL METASTASIS;

EID: 77954809992     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.03.023     Document Type: Article

References (42)

1. O'shauneghnessy J.A., Blum J., Moiseyenko V., Jones S.E., Miles D., Bells D., et al. Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of CMF (cyclophosphamide, methotraxate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001, 12(9):1247-1254.
2. Stockler M.R., Sourjina T., Harvey V., Gebski V., Byrne M., Harvey V., et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 2006, 100(Suppl. 1):S278. [Abstr 6066].
3. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17:485-493.
4. Blum J.L., Dieras V., Russo Lo, Horton J., Rutman O., Buzdar A., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92:1759-1768.
5. Reichardt P., von Minckwitz G., Thuss-Patience P.C., Jonat W., Kolbl H., Janicke F., et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with taxane-containing therapy. Ann Oncol 2003, 14:1227-1233.
6. Fumoleau P., Largillier R., Clippe C., Dieras V., Orfeuvre H., Lesimple T., et al. Multicenter phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004, 40:536-542.
7. Largillier R., Fumoleau P., Clippe C., Dieras V., Orfeuvre H., Lesimple T., et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): long term survival data. Ann Oncol 2006, 17(Suppl. 9). ix74 [Abstr 161P].
8. Mavroudis D., Ardavanis A., Boukovinas I., Varthalitis I., Syrigos K., Potamianou A., et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with anthracycline and taxane chemotherapy: a preliminary report. J Clin Oncol 2006, 24(18S):658.
9. Wist E.A., Sommer H.H., Ostenstad B., Risberg T., Bremnes Y., Mjaaland I., et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004, 43:186-189.
10. Lee S.H., Lee J., Park J., Park S.H., Lee K.E., Lee S.I., et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004, 21:223-231.
11. Kurnianda J., Haryadi A., Aryandono T. Efficacy of capecitabine (X) monotherapy in anthracycline-pretreated metastatic breast cancer (MBC). Preliminary results of phase II study (experience in a single institution). Ann Oncol 2004, 15(Suppl. 3):153.
12. Cervantes G., Torrecillas L., Erazo A., Delgadillo F., Suarez T., Leoner C., et al. Capecitebine (XELODA) as treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol 2000, 19. 121a [Abstr469].
13. Leonard R.C., Twelves C., Breddy J., Chaturvedi A., Hutcheon A., Salasar R., et al. Capecitabine named-patient programme for patients with advanced breast cancer, the UK experience. Eur J Cancer 2002, 38(15):2020-2024.
14. Bajetta E., Procopio G., Celio L., Gattinoni L., Della Tore S., Mariani L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23(10):2155-2161.
15. Hennesy B.T., Gauthier A.M., Michaud L.B., Hortobagyi G., Valero V. Lower dose of capecitabine has more favourable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in literature. Ann Oncol 2005, 16(8):1289-1296.
16. Minea L., Stanculeanu D.L., Cringeanou A., Anghel R.M. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004, 22(Suppl. 14):76s.
17. Longo F., Magnolfi E., Borgomastro A., Gemma D., Salerno M., Alida Ciorra A., et al. Capecitabine(X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC). J Clin Oncol 2004, 22(Suppl. 14S):86s.
18. Debled M, Mandrages N, Mertes C, Floquet A, Donamaria C, Durand M, et al. Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer. 6th European Breast Cancer Conference, 2008, poster 415.
19. Zamora P., Alvarez de Mon M., Calvo L., Jara C., Virizuela J.A., Yubero A., et al. Capecitabine(X) in elderly patients with metastatic breast cancer. Ann Oncol 2004, 15(Suppl. 3). iii40.
20. Surveillance epidemiology and end results cancer statistics review [accessed on 07.05.2009]. http://seer.cancer.gov.
21. Hebert-Croteau, Brisson J., Latreille J., Blanchette C., Deshenes L. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer 1999, 85:1104-1113.
22. Du X.L., Goodwin J.S. Patterns of use of chemotherapy for breast cancer in older women: findings from medicare claims data. J Clin Oncol 2001, 19:1455-1461.
23. Hutchins L.F., Unger J.M., Crowley J.J., Crowley J.J., Coltman C.A., Albain K.S., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 2000, 341:2061-2067.
24. Lewis J.H., Kilgore M.L., Goldman D.P., Trimble E.L., Kaplan R., Montello M.J., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
25. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005, 23:3112-3124.
26. Kemeny M.M., Peterson B.L., Kornblith A.B., Muss H.B., Wheeler J., Levine E., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 21:2268-2275. [Erratum, J Clin Oncol 2004;22:4811].
27. Sateren W.B., Trimble E.L., Abrams J., Brawley O., Breen N., Ford L., et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002, 20:2109-2117.
28. Christman K., Muss H.B., Case L.D., Stanley V. Chemotherapy of metastatic breast cancer in the elderly: the Piermont Oncology Association experience. JAMA 1992, 268:57-62.
29. Ibrahim N.K., Frye D.K., Buzdar A.U., Walters R.S., Hortobagyi G.N. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 1996, 156:882-888.
30. Repetto L., Simoni C., Venturino A., Biancardi V., Gasco M., Campora E., et al. Mitoxantrone in elderly women with advanced breast cancer: a phase II study. Anticancer Res 1995, 2297-3000.
31. Mammoliti S., Merlini L., Caroti C., Gallo L. Phase II study of mitoxantrone, 5-fluorouracil, and leucovorin (MLF) in elderly advanced breast cancer patients. Breast Cancer Res Treat 1996, 37:93-96.
32. Feher O., Vodvarka P., Jassem J., Morak G., Advani S.H., Khoo K.S., et al. First line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicentre, randomized phase 3 study. Ann Oncol 2005, 16:899-908.
33. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin. Cancer Chemother Pharmacol 2003, 51:395-402.
34. Del Maestro L., Perrone F., Repetto L., Manzione L., Zagonel V., Fratino L., et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOger). Ann Oncol 2005, 16:253-258.
35. Hainsworth J.D., Burris H.A., Yardley D.A., Bradof J.E., Grimaldi M., Kalman L.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II Trial. J Clin Oncol 2001, 19:3500-3505.
36. Vogel C., O'Rourke M., Winer E., Hochster H., Chang A., Adamkiewicz B., et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years age or older. Ann Oncol 1999, 10:397-402.
37. Rossi A., Gridelli C., Gebbia V., Rosati G., Tortoriello A., Maione P., et al. Single agent vinorelbine as first line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003, 23:1657-1664.
38. Bajetta M., Suman V.J., Fitch T.R., Maillard J.A., Bernath A., Rowland K.M., et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ≥65 years of age: an NCCTG study. Ann Oncol 2006, 17:623-629.
39. Basso U., Fratino L., Brunello A., Lumachi F., De Salvo L., Lonardi S., et al. Which benefit from adding gemcitabine to vinorelbine in elderly (>70 years) women with metastatic breast cancer? Early interruption of a phase 2 study. Ann Oncol 2007, 18:58-63.
40. O'Shaughnesy J. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann Oncol 2002, 13:983.
41. Talbot D.C., Moiyesenko V., Van Belle S., O'Reilly S.M., Alba Conejo E., Ackland S., et al. Randomized phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002, 86:1367-1372.
42. Yap Y.S., Kendall A., Walsh G., Banerji U., Johnston S.R.D., Smith I.E., et al. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer-How long can you go?. The Breast 2007, 16:420-424.